Neurocrine Biosciences to Participate at Investor Conferences in December
Neurocrine Biosciences (NBIX) has announced its participation in two major investor conferences this December. The company will present at The 7th Annual Evercore HealthCONx Conference on December 3 at 10:50 a.m. ET in Coral Gables, Florida, and Citi's 2024 Global Healthcare Conference on December 4 at 1:45 p.m. ET in Miami.
The presentations will be accessible via webcast on Neurocrine's website, with replays available for approximately one month. The company, focused on neuroscience and biopharmaceuticals, develops treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with FDA-approved treatments for conditions including tardive dyskinesia, Huntington's disease chorea, endometriosis, and uterine fibroids.
Neurocrine Biosciences (NBIX) ha annunciato la sua partecipazione a due importanti conferenze per investitori questo dicembre. L'azienda presenterà alla 7ª Conferenza Annuale Evercore HealthCONx il 3 dicembre alle 10:50 a.m. ET a Coral Gables, Florida, e alla Conferenza Sanitaria Globale 2024 di Citi il 4 dicembre alle 1:45 p.m. ET a Miami.
Le presentazioni saranno accessibili tramite webcast sul sito web di Neurocrine, con repliche disponibili per circa un mese. L'azienda, che si concentra sulle neuroscienze e sui farmaceutici, sviluppa trattamenti per disturbi neurologici, neuroendocrini e neuropsichiatrici, con trattamenti approvati dalla FDA per condizioni come la dischinesia tardiva, la corea di Huntington, l'endometriosi e i fibromi uterini.
Neurocrine Biosciences (NBIX) ha anunciado su participación en dos importantes conferencias de inversores este diciembre. La compañía presentará en la 7ª Conferencia Anual Evercore HealthCONx el 3 de diciembre a las 10:50 a.m. ET en Coral Gables, Florida, y en la Conferencia Global de Salud 2024 de Citi el 4 de diciembre a la 1:45 p.m. ET en Miami.
Las presentaciones estarán disponibles a través de un webcast en el sitio web de Neurocrine, con repeticiones disponibles durante aproximadamente un mes. La empresa, enfocada en neurociencias y biofarmacéuticos, desarrolla tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos, con tratamientos aprobados por la FDA para condiciones como la discinesia tardía, la corea de Huntington, la endometriosis y los fibromas uterinos.
뉴로크라인 바이오사이언스 (NBIX)는 이번 12월에 두 개의 주요 투자자 회의에 참석한다고 발표했습니다. 회사는 플로리다주 코랄 게이블스에서 12월 3일 오전 10시 50분 ET에 제7회 에버코어 헬스CONx 컨퍼런스에서 발표하며, 마이애미에서 12월 4일 오후 1시 45분 ET에 씨티의 2024 글로벌 헬스케어 컨퍼런스에서 발표할 예정입니다.
발표는 뉴로크라인 웹사이트에서 웹캐스트를 통해 접근할 수 있으며, 약 한 달 동안 재생 가능할 것입니다. 신경과학 및 바이오 제약에 중점을 둔 이 회사는 지연성 운동 장애, 헌팅턴병 무도병, 자궁내막증 및 자궁 섬유종과 같은 질환에 대한 FDA 승인 치료제를 개발합니다.
Neurocrine Biosciences (NBIX) a annoncé sa participation à deux importantes conférences pour investisseurs ce décembre. La société présentera à la 7e Conférence Annuelle Evercore HealthCONx le 3 décembre à 10h50 ET à Coral Gables, en Floride, et à la Conférence Mondiale de la Santé 2024 de Citi le 4 décembre à 13h45 ET à Miami.
Les présentations seront accessibles via webcast sur le site web de Neurocrine, avec des rediffusions disponibles pendant environ un mois. L'entreprise, axée sur les neurosciences et les biopharmaceutiques, développe des traitements pour les troubles neurologiques, neuroendocriniens et neuropsychiatriques, avec des traitements approuvés par la FDA pour des affections telles que la dyskinésie tardive, la chorée de Huntington, l'endométriose et les fibromes utérins.
Neurocrine Biosciences (NBIX) hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen im Dezember angekündigt. Das Unternehmen wird am 3. Dezember um 10:50 Uhr ET auf der 7. Jahrestagung der Evercore HealthCONx in Coral Gables, Florida, und am 4. Dezember um 13:45 Uhr ET auf der Citi's 2024 Global Healthcare Conference in Miami präsentieren.
Die Präsentationen werden über einen Webcast auf der Website von Neurocrine zugänglich sein, mit Wiederholungen, die etwa einen Monat lang verfügbar sind. Das Unternehmen, das sich auf Neurowissenschaften und Biopharmazeutika konzentriert, entwickelt Behandlungen für neurologische, neuroendokrine und neuropsychiatrische Erkrankungen mit von der FDA zugelassenen Therapien für Erkrankungen wie tardive Dyskinesie, Chorea Huntington, Endometriose und Uterusmyome.
- None.
- None.
The 7th Annual Evercore HealthCONx Conference on December 3
Citi's 2024 Global Healthcare Conference on December 4
- The 7th Annual Evercore HealthCONx Conference at 10:50 a.m. Eastern Time on Tuesday December 3, 2024 in
Coral Gables, Florida . - Citi's 2024 Global Healthcare Conference at 1:45 p.m. Eastern Time on Wednesday December 4, 2024 in
Miami .
The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-december-302316899.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences (NBIX) presenting at the Evercore HealthCONx Conference 2024?
Where can I watch Neurocrine Biosciences' (NBIX) December 2024 investor conference presentations?
What medical conditions does Neurocrine Biosciences (NBIX) currently have FDA-approved treatments for?
When is Neurocrine Biosciences (NBIX) presenting at Citi's 2024 Global Healthcare Conference?
